Limitations of targeted therapy with sorafenib in elderly high-risk myelodysplastic syndrome and acute myeloid leukemia

Leuk Lymphoma. 2013 Apr;54(4):675-6. doi: 10.3109/10428194.2012.731604. Epub 2012 Oct 4.

Authors

Andrew Wei¹, Peter Tan

Affiliation

¹ Department of Clinical Hematology, The Alfred Hospital, Melbourne, Australia. a.wei@alfred.org.au

PMID: 22988956
DOI: 10.3109/10428194.2012.731604

No abstract available

Publication types

Comment

MeSH terms

Female
Humans
Leukemia, Myeloid, Acute / drug therapy*
Male
Myelodysplastic Syndromes / drug therapy*
Niacinamide / administration & dosage
Niacinamide / analogs & derivatives*
Phenylurea Compounds / administration & dosage*
Sorafenib

Substances

Phenylurea Compounds
Niacinamide
Sorafenib